Vernal Keratoconjunctivitis Clinical Trial
Official title:
Topical Tacrolimus in Vernal Keratoconjunctivitis
The main aim of this study is to evaluate the efficacy and safety of topical tacrolimus 0.01% eyedrops in patients with vernal keratoconjunctivitis.
A total of 20 patients with bilateral symmetrical vernal keratoconjunctivitis will be included. Each patient will undergo a complete ophthalmologic evaluation. Patient will be placed at random on topical Tacrolimus 0.01% ophthalmic solution in one eye and placebo eyedrops in the fellow eye. Patients will undergo ophthalmologic examination at one week and after one month. Photos will be taken. The outcome measures include graded symptoms, graded signs, and laboratory investigations. Symptoms of itching, redness, foreign body sensation, tearing and discharge following will be recorded before and after treatment. The grading of clinical signs of conjunctival hyperemia, conjunctival papillary hypertrophy, perilimbal infiltrates, Trantas dots, superficial punctate keratopathy will be recorded before and after treatment. Conjunctival surface temperature will be determined before and after treatment. Conjunctival scrapings will be stained with Giemsa and will be assessed before and after therapy and number of eosinophils per hpf will be determined and recorded. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05076084 -
Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis
|
||
Recruiting |
NCT02057822 -
Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months
|
N/A | |
Completed |
NCT03464435 -
A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis
|
Phase 4 | |
Completed |
NCT00445120 -
Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT03557203 -
Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis
|
||
Completed |
NCT01211327 -
Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda
|
Phase 4 | |
Completed |
NCT05353101 -
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
|
Phase 1 | |
Not yet recruiting |
NCT04705584 -
Topical Immuonosuppressant Drugs in Spring Catarrh
|
N/A | |
Completed |
NCT03379311 -
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
|
Phase 1 | |
Completed |
NCT00426023 -
Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis
|
Phase 3 | |
Completed |
NCT01751126 -
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
|
Phase 3 |